1440P - Evaluation of outcome and prognostic factors in synovial sarcoma: A single large institutional study of 139 cases

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cancer Aetiology, Epidemiology, Prevention
Sarcoma
Presenter Nida Iqbal
Citation Annals of Oncology (2014) 25 (suppl_4): iv494-iv510. 10.1093/annonc/mdu354
Authors N. Iqbal1, N. Shukla2, S.V.S. Deo3, S. Agarwala4, M.C. Sharma5, S. Bakhshi6
  • 1Medical Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Dept. Of Surgical Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN
  • 3Surgical Oncology, AIIMS, 110029 - New Delhi/IN
  • 4Pediatric Surgery, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 5Pathology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 6Dept. Of Medical Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN

Abstract

Aim

Synovial sarcoma (SS) is one of the most common soft tissue sarcomas in adolescents and young patients.Due to minimal data on clinical behaviour in literature, we reviewed our institutional experience with SS treated with multimodality therapy.

Methods

Data on patients with confirmed SS diagnosed between June 2003 and December 2012 was retrieved from the database. Patient and tumor characteristics were evaluated for treatment outcome and prognostic factors.

Results

Out of 952 soft-tissue sarcoma patients in the study period, 173 (18%) SS patients were identified, of which 139 were analysable. Median age was 30 years (range 2-72 years) with a male:female ratio of 2:1.Forty-three (31%) patients were metastatic at baseline. Ninety-seven (70%) patients underwent surgery, of which amputation was done in 25 patients. Thirty-two patients received adjuvant chemoradiotherapy,31 patients adjuvant chemotherapy alone and 11 patients adjuvant radiotherapy alone. Metastasectomy was done in 6 patients. At a median follow-up of 43 months (range 1-98 months), 5-year event-free survival (EFS) and overall survival (OS) were 28% and 37% respectively, for the entire cohort, and 39% and 51% respectively, for patients with localized disease. In multivariate analysis of whole cohort, baseline metastases (p=0.002) and non-surgical treatment (p=0.02) were associated with inferior OS whereas for localized disease, tumor size>or=to 10 cm (p=0.01) and non-surgical treatment (p=0.05) predicted inferior EFS and male sex (p=0.02) and non-surgical treatment (p=0.000) were associated with inferior OS. Monophasic histology (p=0.01) was associated with inferior progression-free survival (PFS) in metastatic group.

Conclusions

This is a single large-institutional study of patients with SS. Male sex, larger tumors, truncal location, monophasic histology, unresectable and metastatic disease are identified as adverse prognostic factors.

Disclosure

All authors have declared no conflicts of interest.